公开(公告)号：US20160185850A1

公开(公告)日：2016-06-30

申请号：US15064067

申请日：2016-03-08

申请人： ESBATech, an Alcon Biomedical Research Unit LLC

发明人： Stefan Ewert ,  David Urech ,  Adrian Auf Der Maur ,  Alcide Barberis ,  Peter Lichtlen

IPC分类号： C07K16/24

CPC分类号： C07K16/241 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/522 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNFα-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.

摘要翻译： 本发明涉及特别稳定和可溶的scFv抗体和对TNFα特异性的Fab片段，其包含针对TNFα的稳定性，溶解性，体外和体内结合而优化的特异性轻链和重链序列以及低免疫原性。 所述抗体被设计用于诊断和/或治疗TNFα相关疾病。 还公开了用于表达本发明的重组抗体的核酸，载体和宿主细胞，用于分离它们的方法和所述抗体在医学中的用途。